|
6 Companies |
|
4 Products |
|
4 Products |
|
2 Mechanisms of Action |
|
0 Trials |
|
81 News |
|
| 12» |
- | Trial completion, Trial primary completion date: BETTUR PD: Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease (clinicaltrials.gov) - Jan 10, 2018
P3, N=53, Completed, Sponsor: Atlanta VA Medical Center
Recruiting --> Completed | Trial primary completion date: Mar 2017 --> Aug 2017
- ||||| Vesicare (solifenacin) / Astellas
Enrollment change, Monotherapy: SYNERGY: This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (clinicaltrials.gov) - Oct 3, 2017
P3, N=3527, Completed, Sponsor: Astellas Pharma Europe B.V.
Recruiting --> Completed | Trial primary completion date: Mar 2017 --> Aug 2017 N=6991 --> 3527
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment change, Trial termination: Randomization of Botox for Stent Pain and Irritative Voiding Symptoms (clinicaltrials.gov) - May 25, 2017
P3, N=15, Terminated, Sponsor: University of California, Irvine
N=6991 --> 3527 N=80 --> 15 | Recruiting --> Terminated; The study was terminated due to low enrollment
- | armodafinil / Generic mfg.
Enrollment change: Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia (clinicaltrials.gov) - Mar 24, 2017
P2/3, N=81, Completed, Sponsor: Duke University
N=80 --> 15 | Recruiting --> Terminated; The study was terminated due to low enrollment N=27 --> 81
- |||| silodosin / Generic mfg.
Trial completion, Trial primary completion date: Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia (clinicaltrials.gov) - Mar 10, 2017
P4, N=135, Completed, Sponsor: JW Pharmaceutical
N=27 --> 81 Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Mar 2016
- Trial primary completion date: BETTUR PD: Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease (clinicaltrials.gov) - Jan 26, 2017
P3, N=60, Recruiting, Sponsor: Atlanta VA Medical Center
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Mar 2016 Trial primary completion date: Dec 2016 --> Mar 2017
- Phase classification: Efficacy and Safety of Gabapentin in Treating Overactive Bladder (clinicaltrials.gov) - Jan 4, 2017
P2/3, N=94, Completed, Sponsor: Michael E. Chua
Trial primary completion date: Dec 2016 --> Mar 2017 Phase classification: P4 --> P2/3
- ||||||| Vesicare (solifenacin) / Astellas
Trial completion, Monotherapy: A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (clinicaltrials.gov) - Dec 2, 2016
P3, N=2084, Completed, Sponsor: Astellas Pharma Europe B.V.
Phase classification: P4 --> P2/3 Active, not recruiting --> Completed
- fesoterodine / Generic mfg., desmopressin / Generic mfg.
Enrollment change, Trial initiation date, Trial termination, Trial primary completion date: Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older (clinicaltrials.gov) - Nov 15, 2016
P2/3, N=4, Terminated, Sponsor: Mount Sinai Hospital, Canada
Active, not recruiting --> Completed N=132 --> 4 | Initiation date: Dec 2014 --> Jul 2015 | Not yet recruiting --> Terminated | Trial primary completion date: May 2016 --> Feb 2016; Poor recruitment
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial primary completion date: Randomization of Botox for Stent Pain and Irritative Voiding Symptoms (clinicaltrials.gov) - Nov 7, 2016
P3, N=80, Recruiting, Sponsor: University of California, Irvine
N=132 --> 4 | Initiation date: Dec 2014 --> Jul 2015 | Not yet recruiting --> Terminated | Trial primary completion date: May 2016 --> Feb 2016; Poor recruitment Trial primary completion date: Feb 2015 --> Feb 2017
- Trial completion, Enrollment change, Trial primary completion date: Study of Idiopathic Edema (clinicaltrials.gov) - Nov 3, 2016
P=N/A, N=4, Completed, Sponsor: Winthrop University Hospital
Trial primary completion date: Feb 2015 --> Feb 2017 Recruiting --> Completed | N=75 --> 4 | Trial primary completion date: May 2018 --> Nov 2016
- ||| desmopressin / Generic mfg.
Trial completion: A Study of Minirin Melt in 24 Months Treatment in Patients With Nocturia (clinicaltrials.gov) - May 24, 2016
P=N/A, N=4136, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed | N=75 --> 4 | Trial primary completion date: May 2018 --> Nov 2016 Active, not recruiting --> Completed
- Enrollment change: Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness (clinicaltrials.gov) - Apr 14, 2016
P4, N=0, Withdrawn, Sponsor: Cognitive Research Corporation
Active, not recruiting --> Completed N=24 --> 0
- armodafinil / Generic mfg.
Trial completion: Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia (clinicaltrials.gov) - Jan 22, 2016
P2/3, N=27, Completed, Sponsor: Duke University
N=24 --> 0 Recruiting --> Completed
- Trial primary completion date: Study of Idiopathic Edema (clinicaltrials.gov) - Dec 12, 2015
P=N/A, N=75, Recruiting, Sponsor: Winthrop University Hospital
Recruiting --> Completed Trial primary completion date: Dec 2012 --> May 2018
- ||||||| Vesicare (solifenacin) / Astellas
Trial completion, Monotherapy: SYNERGY: This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (clinicaltrials.gov) - Nov 21, 2015
P3, N=6991, Completed, Sponsor: Astellas Pharma Europe B.V.
Trial primary completion date: Dec 2012 --> May 2018 Active, not recruiting --> Completed
- ||||| Vesicare (solifenacin) / Astellas
Enrollment closed, Monotherapy: A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (clinicaltrials.gov) - Aug 26, 2015
P3, N=2086, Active, not recruiting, Sponsor: Astellas Pharma Europe B.V.
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ||||| Vesicare (solifenacin) / Astellas
Enrollment closed, Enrollment change, Monotherapy: SYNERGY: This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (clinicaltrials.gov) - Aug 11, 2015
P3, N=6480, Active, not recruiting, Sponsor: Astellas Pharma Europe B.V.
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting | N=3392 --> 6480
- Vesicare (solifenacin) / Astellas
Trial primary completion date, Monotherapy: A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (clinicaltrials.gov) - Apr 27, 2015
P3, N=2400, Enrolling by invitation, Sponsor: Astellas Pharma Europe B.V.
Recruiting --> Active, not recruiting | N=3392 --> 6480 Trial primary completion date: Feb 2016 --> Oct 2016
- Vesicare (solifenacin) / Astellas
Trial primary completion date, Monotherapy: SYNERGY: This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (clinicaltrials.gov) - Apr 16, 2015
P3, N=3392, Recruiting, Sponsor: Astellas Pharma Europe B.V.
Trial primary completion date: Feb 2016 --> Oct 2016 Trial primary completion date: Jun 2015 --> Oct 2015
- Trial completion, Enrollment change: Efficacy and Safety of Gabapentin in Treating Overactive Bladder (clinicaltrials.gov) - Apr 7, 2015
P4, N=94, Completed, Sponsor: St. Luke's Medical Center, Philippines
Trial primary completion date: Jun 2015 --> Oct 2015 Active, not recruiting --> Completed | N=120 --> 94
- desmopressin / Generic mfg.
Enrollment change, Trial termination: Clinical Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients (clinicaltrials.gov) - Feb 5, 2015
P3, N=9, Terminated, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed | N=120 --> 94 N=80 --> 9 | Recruiting --> Terminated; Insufficient funding
- Trial primary completion date: BETTUR PD: Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease (clinicaltrials.gov) - Jan 18, 2015
P3, N=60, Recruiting, Sponsor: Atlanta VA Medical Center
N=80 --> 9 | Recruiting --> Terminated; Insufficient funding Trial primary completion date: Dec 2015 --> Dec 2016
- Vesicare (solifenacin) / Astellas
Trial primary completion date, Monotherapy: SYNERGY: This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (clinicaltrials.gov) - Jan 8, 2015
P3, N=3392, Recruiting, Sponsor: Astellas Pharma Europe B.V.
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Mar 2015 --> Jun 2015
- ||| desmopressin / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion (clinicaltrials.gov) - Dec 12, 2014
P=N/A, N=64, Completed, Sponsor: University of Aarhus
Trial primary completion date: Mar 2015 --> Jun 2015 Recruiting --> Completed | N=80 --> 64 | Trial primary completion date: Jul 2014 --> Dec 2014
- | armodafinil / Generic mfg.
Trial primary completion date: Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia (clinicaltrials.gov) - Dec 7, 2014
P2/3, N=30, Recruiting, Sponsor: Duke University
Recruiting --> Completed | N=80 --> 64 | Trial primary completion date: Jul 2014 --> Dec 2014 Trial primary completion date: Dec 2014 --> Jun 2015
- |||| desmopressin / Generic mfg.
Trial completion, Combination therapy: Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women (clinicaltrials.gov) - Dec 5, 2014
P2, N=106, Completed, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Dec 2014 --> Jun 2015 Active, not recruiting --> Completed
- desmopressin / Generic mfg.
Trial completion: Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic/Dynamic Study (clinicaltrials.gov) - Dec 5, 2014
P4, N=50, Completed, Sponsor: University Hospital, Ghent
Active, not recruiting --> Completed Recruiting --> Completed
- ||| desmopressin / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: The Effect of Combined Systematized Behavioural Modification Education Program (SyBeMeP) With DDAVP in Patients With Nocturia (clinicaltrials.gov) - Nov 20, 2014
P=N/A, N=124, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Completed Recruiting --> Completed | N=200 --> 124 | Trial primary completion date: Feb 2014 --> Oct 2014
- Enrollment closed, Trial initiation date: Efficacy and Safety of Gabapentin in Treating Overactive Bladder (clinicaltrials.gov) - Oct 17, 2014
P4, N=120, Active, not recruiting, Sponsor: St. Luke's Medical Center, Philippines
Recruiting --> Completed | N=200 --> 124 | Trial primary completion date: Feb 2014 --> Oct 2014 Recruiting --> Active, not recruiting | Initiation date: Jan 2012 --> Oct 2010
- || fesoterodine / Generic mfg., desmopressin / Generic mfg.
New P2/3 trial: Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older (clinicaltrials.gov) - Oct 15, 2014
P2/3, N=132, Not yet recruiting, Sponsor: Mount Sinai Hospital, Canada
- ||| Clinical: The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=5775, Completed, Sponsor: Boehringer Ingelheim
- ||| desmopressin / Generic mfg.
Enrollment closed, Combination therapy: Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women (clinicaltrials.gov) - Sep 5, 2014
P2, N=100, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting | Initiation date: Jan 2012 --> Oct 2010 Recruiting --> Active, not recruiting
- Enrollment change, Trial withdrawal, Trial primary completion date: Severe Pelvic Organ Prolapse and Post-Obstructive Diuresis (SOPPO) Pilot Study (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=0, Withdrawn, Sponsor: Loyola University
Recruiting --> Active, not recruiting N=25 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2015 --> Jan 2014
- || desmopressin / Generic mfg.
Trial primary completion date, Combination therapy: Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women (clinicaltrials.gov) - Aug 21, 2014
P2, N=100, Recruiting, Sponsor: Ferring Pharmaceuticals
N=25 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2015 --> Jan 2014 Trial primary completion date: Jul 2014 --> Dec 2014
- desmopressin / Generic mfg.
Trial primary completion date: Clinical Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients (clinicaltrials.gov) - Jul 23, 2014
P3, N=80, Recruiting, Sponsor: Chinese University of Hong Kong
Trial primary completion date: Jul 2014 --> Dec 2014 Trial primary completion date: Feb 2014 --> Feb 2015
- || desmopressin / Generic mfg.
Enrollment closed: A Study of Minirin Melt in 24 Months Treatment in Patients With Nocturia (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=4100, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Feb 2014 --> Feb 2015 Recruiting --> Active, not recruiting
- Trial primary completion date: Spanish (Spain) Validation of a Specific Symptomatic Questionnaire for Patients With Nocturia (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=129, Completed, Sponsor: Corporacion Parc Tauli
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Feb 2014
- Trial completion, Trial primary completion date: Spanish (Spain) Validation of a Specific Symptomatic Questionnaire for Patients With Nocturia (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=129, Completed, Sponsor: Corporacion Parc Tauli
Trial primary completion date: Jun 2014 --> Feb 2014 Recruiting --> Completed | Trial primary completion date: Jun 2014 --> Feb 2014
- armodafinil / Generic mfg.
New P2/3 trial: Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia (clinicaltrials.gov) - May 27, 2014
P2/3, N=30, Recruiting, Sponsor: Duke University
- armodafinil / Generic mfg.
Enrollment open: Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia (clinicaltrials.gov) - May 27, 2014
P2/3, N=30, Recruiting, Sponsor: Duke University
Recruiting --> Completed | Trial primary completion date: Jun 2014 --> Feb 2014 Not yet recruiting --> Recruiting
- ||||| silodosin / Generic mfg.
New P4 trial: Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia (clinicaltrials.gov) - Apr 6, 2014
P4, N=126, Recruiting, Sponsor: JW Pharmaceutical
- |||| silodosin / Generic mfg.
Enrollment open: Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia (clinicaltrials.gov) - Apr 6, 2014
P4, N=126, Recruiting, Sponsor: JW Pharmaceutical
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || desmopressin / Generic mfg.
Enrollment change: A Study of Minirin Melt in 24 Months Treatment in Patients With Nocturia (clinicaltrials.gov) - Mar 30, 2014
P=N/A, N=3500, Recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting N=2500 --> 3500
- |||||| Vesicare (solifenacin) / Astellas
Enrollment open, Monotherapy: A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (clinicaltrials.gov) - Mar 20, 2014
P3, N=2400, Enrolling by invitation, Sponsor: Astellas Pharma Europe BV
N=2500 --> 3500 Not yet recruiting --> Enrolling by invitation
- desmopressin / Generic mfg.
Trial termination: DAISS: Daytime Impact Sleep Study (clinicaltrials.gov) - Mar 5, 2014
P2, N=6, Terminated, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Enrolling by invitation Recruiting --> Terminated; Terminated due to lack of eligible patients
- desmopressin / Generic mfg.
Enrollment change: DAISS: Daytime Impact Sleep Study (clinicaltrials.gov) - Mar 5, 2014
P2, N=6, Terminated, Sponsor: Ferring Pharmaceuticals
Recruiting --> Terminated; Terminated due to lack of eligible patients N=48 --> 6
- || Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
New P3 trial: Randomization of Botox for Stent Pain and Irritative Voiding Symptoms (clinicaltrials.gov) - Mar 3, 2014
P3, N=80, Recruiting, Sponsor: University of California, Irvine
- |||||||||| Vesicare (solifenacin) / Astellas
New P3 trial, Monotherapy: A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (clinicaltrials.gov) - Jan 23, 2014
P3, N=2400, Enrolling by invitation, Sponsor: Astellas Pharma Europe BV
- ||| desmopressin / Generic mfg.
Trial completion: A Study of Minirin Melt in Patients With Nocturia (clinicaltrials.gov) - Jan 2, 2014
P=N/A, N=2187, Completed, Sponsor: Ferring Pharmaceuticals
N=48 --> 6 Active, not recruiting --> Completed